Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population

Figure 4

Anti-RBD IgG antibodies and neutralization activity during active infection with SARS-CoV-2. (a) Anti-RBD IgG levels in participants, namely, healthy controls as the baseline group () and active COVID-19 patients with different degrees of severity (). (b) contingence analysis for positive/negative antibody levels and days of symptom onset, age (years), neutralization activity and for high/low neutralization activity (median ID80) and days of symptom onset. 75th percentile (P75) is indicated in red circles, and IgG cut-off is indicated by a black dashed line.

(a)

(b)